C12N 2760/18471
Demonstrated in vivo effect
C12N2760/18471 (Demonstrated in vivo effect) appears on 14 US grants and 22 published applications in this corpus.
Search patents in C12N- Granted patents
- 14
- Published applications
- 22
- Assignees
- 19
- Inventors
- 41
- Latest grant
- 20 May 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 1 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 2 |
| 2014 | 0 | 0 |
| 2015 | 0 | 3 |
| 2016 | 2 | 3 |
| 2017 | 2 | 2 |
| 2018 | 1 | 1 |
| 2019 | 2 | 0 |
| 2020 | 0 | 2 |
| 2021 | 1 | 2 |
| 2022 | 3 | 0 |
| 2023 | 0 | 2 |
| 2024 | 1 | 2 |
| 2025 | 2 | 0 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- RNA viruses for immunovirotherapy20 May 2025US 12,303,540 B2Deutsches Krebsforschung-Szentrum, Ruprecht-Karls-Universitat Heidelberg
- Methods of vaccine administration6 May 2025US 12,290,559 B2Zoetis Services LLC
- Lassa vaccine7 May 2024US 11,976,305 B2Centre National De La Recherche Scientifique
- Methods of vaccine administration13 Dec 2022US 11,524,067 B2Zoetis Services LLC
- Methods of vaccine administration13 Dec 2022US 11,524,068 B2Zoetis Services LLC
- Human ctla-4 peptide vaccines and uses thereof8 Jan 2026US 2026/0007730 A1Ohio State Innovation Foundation
- Retargeted retroviral vectors resistant to vaccine-induced neutralization and compositions or methods of use thereof19 Sep 2024US 2024/0307555 A1The Broad Institute, Inc.
- Retargeted retroviral vectors and compositions or methods of use thereof5 Sep 2024US 2024/0294942 A1The Broad Institute, Inc.
- Methods Of Vaccine Administration16 Mar 2023US 2023/0078668 A1Zoetis Services LLC
- Measles virus encoding a tumor antigen9 Mar 2023US 2023/0069933 A1Ruprecht-Karls-UniversitäT Heidelberg
Most cited
By later US patents